Showing results (31-40 of 644) with videos related to
Sort By:
Pageof 65
Therapeutics and Clinical Risk Management|April 28, 2010
Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemiaAyman A Hussein, Stephen J NichollsCurrent Atherosclerosis Reports|November 21, 2022
CETP Inhibitors: Should We Continue to Pursue This Pathway?Stephen J Nicholls, Adam J NelsonJournal of Lipid Research|December 19, 2008
Myeloperoxidase, modified lipoproteins, and atherogenesisStephen J Nicholls, Stanley L HazenAmerican Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 26, 2019
Rivaroxaban With or Without Aspirin for the Secondary Prevention of Cardiovascular Disease: Clinical Implications of the COMPASS TrialStephen J Nicholls, Adam J NelsonAmerican Journal of Preventive Cardiology|July 20, 2022
Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imagingGiuseppe Di Giovanni, Stephen J NichollsAmerican Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 6, 2019
Do Cholesteryl Ester Transfer Protein Inhibitors Have a Role in the Treatment of Cardiovascular Disease?Stephen J Nicholls, Adam J NelsonCleveland Clinic Journal of Medicine|December 28, 2017
Results of the GLAGOV trialSteven E Nissen, Stephen J NichollsArteriosclerosis, Thrombosis, and Vascular Biology|March 26, 2005
Myeloperoxidase and cardiovascular diseaseStephen J Nicholls, Stanley L HazenPageof 65